Horizon announces issuance of additional notice of allowance for Pennsaid 2% Horizon Pharma announced it received a Notice of Allowance from the United States Patent and Trademark Office for U.S. patent application number 14/497,096, entitled "Diclofenac Topical Formulation" that covers Horizon's U.S. approved product PENNSAID 2% w/w. This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The U.S. patent scheduled to issue from this application will expire in 2027. After issuance, Horizon plans to list the patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. This will be the ninth U.S. patent to be listed in the Orange Book for PENNSAID 2%.